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Abstract
Background: CYP1B1 is a P450 enzyme which is involved in the activation of pro-carcinogens to carcinogens as
well as sex hormone metabolism. Because differences in the activity of the enzyme have been correlated with
variant alleles of single nucleotide polymorphisms (SNPs), it represents an attractive candidate gene for studies into
colorectal cancer susceptibility.
Methods: We genotyped 597 cancer patients and 597controls for three CYP1B1 SNPs, which have previously been
shown to be associated with altered enzymatic activity. Using the three SNPs, eight different haplotypes were
constructed. The haplotype frequencies were estimated in cases and controls and then compared. The odds ratio
for each tumour type, associated with each haplotype was estimated, with reference to the most common
haplotype observed in the controls.
Results: The three SNPs rs10012, rs1056827 and rs1056836 alone did not provide any significant evidence of
association with colorectal cancer risk. Haplotypes of rs1056827 and rs10012 or rs1056827 and rs1056836 revealed
an association with colorectal cancer which was significantly stronger in the homozygous carriers. One haplotype
was under represented in the colorectal cancer patient group compared to the control population suggesting a
protective effect.
Conclusion: Genetic variants within the CYP1B1 that are associated with altered function appear to influence
susceptibility to a colorectal cancer in Poland. Three haplotypes were associated with altered cancer risk; one
conferred protection and two were associated with an increased risk of disease. These observations should be
confirmed in other populations.
Background
Adverse interactions between DNA and environmental
toxins may be mitigated through a range of biologic
defense mechanisms, including DNA repair, cell cycle
checkpoint control and xenobiotic clearance enzymes.
Xenobiotic clearance is important for the removal of
carcinogens and is primarily accomplished by hydroxyl
conjugation, involving enzymes in the cytochrome P450
pathway [1]. Cancers of the colon, lung, larynx, kidney
and pancreas have been shown to be associated with
environmental exposures to various carcinogens [2,3]
and polymorphisms in several key enzymes involved in
xenobiotic clearance have been linked to the risks of
various cancers. One enzyme of particular importance is
CYP1B1, which is encoded by a polymorphic gene [3].
A number of polymorphisms in this gene have been
shown to affect the activity of the encoded protein [4,5].
Four polymorphisms, occurring at codons rs10012,
rs1056827, rs1056836 and rs1800440, all of which result
in single amino acid substitutions that result in an
altered enzyme activity are of particular interest [5].
CYP1B1 is primarily involved in the hydroxylation of
17b-estradiol at the 2-OH and 4-OH positions, which
can then be oxidized to semiquinones and quinines [1].
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bolites that can form DNA adducts thereby potentially
introducing mutations into the genome [6]. Generation
of 2-OH catechol estrogens does not appear to result in
deleterious affects whereas the 4-OH catechol derivative
has been shown to be associated with an increase in
DNA single strand breaks as well as increased nuclear
levels of 8-hydroxyguanosine [5,7,8]. Both of these unde-
sirable outcomes alter the risk of malignancy by increas-
ing the likelihood of introducing mutations into the
genome and consequently the risk of malignancy.
As part of a major initiative to identify major cancer
susceptibility genes for colorectal cancer, we investigated
three common variants in the CYP1B1 gene that indivi-
dually confer a difference in the activity of the encoded
protein. All three variants, codon 48G > C (rs10012),
codon 119G > T (rs1056827) and 432 G > C (rs1056836)
have been shown to result in an increased metabolism of
16a-OH-estradiol [5]. An investigation of three of the
CYP1B1 SNP polymorphisms was undertaken to deter-
mine whether, alone or in combination, these SNPs were
associated with an altered likelihood of disease. A fourth
CYP1B1 variant, SNP 453A > G (rs1800440) was not
investigated in the present study because it does not
occur at sufficiently high frequency to allow a meaningful
analysis.
Methods
Study subjects
The Polish population is extremely homogeneous and
lends itself to population based studies as there are no
significant ethnic differences to take into consideration.
597 colorectal cancer patients were enrolled in the
study. Enrollment occurred between 1998 and 2006
from 3 cities in Poland (Table 1). Patients were asked to
participate during a visit to the outpatient oncology
departments of the various participating hospitals
affiliated with the Hereditary Cancer Center in Szczecin.
To estimate the prevalence of the various CYP1B1 geno-
types and haplotypes in the underling Polish population,
597 sex and age-matched controls were invited to parti-
cipate in the study all of whom resided in the city and
surrounds of Szczecin.
The study protocol was approved by the ethics com-
mittee of the Pomeranian Medical University and each
participant signed a consent form for the study prior to
enrolment.
DNA isolation
DNA was extracted from peripheral blood lymphocytes
of individuals using the non-enzymatic, rapid method
without modification [9].
Polymorphism Analysis
The A119 S variant was identified by restriction frag-
ment length polymorphism PCR using CTCGTTCGCT
CGCCTGGCGC and GAAGTTGCGCATCATGCTGT
primers. The PCR reactions was carried out in PTC-200
Peltier DNA Thermal Cycler MJ Research. Detailed
experimental PCR conditions are available on request.
Amplified DNA was digested with Eam 1105I enzyme
and size separated on a 3% agarose gel. The PCR pro-
duct length, before and after digestion were 136 base
pairs (bp) and 114 bp, respectively (see Fig 1) All posi-
tive results were verified by a reverse RFLP-PCR using a
Pdil enzyme (Fermentas, St Leon Rot, Germany). Finally,
a random selection of cases harbouring the GG, GT or
TT genotypes were subjected to direct sequencing using
the BigDye Terminator Ready Reaction Kit v3.0
(Applied Biosystems, Foster City, CA) and analyzed in
an ABI PRISM 377 DNA sequencer (data not shown).
A similar protocol was performed for the 142G > C
and 432C > G change using the primer pairs TCCATC-
CAGCAGACCACGCT and GCCGGACACCACACG-
GAAG and ATGCGCTTCTCCAGCTTTGT and
TATGGAGCACACCTCACCTG, respectively.
The 142G > C polymorphism was identified using the
restriction enzyme AvaI enzyme (Fermentas). The resul-
tant products were size separated on 4% agarose gels.
The uncut product was 335 bp in size and the cut pro-
duct was predicted to yield 4 fragments of 230,105, 91
a n d1 4b pi ns i z e .O n l yt h e2 3 0 , 1 0 5a n d9 1b a s ep a i r
Table 1 Sites and period of specimen collection for the
patients samples
Colon
Time period of collection of cases 1998-2006
Hospitals where patients were collected Bielsko-Biała
Bydgoszcz
Szczecin
Age range of diagnosis 21-92
Figure 1 Representative gel of RFLP-PCR for change 355G > T
(A119S). Lanes: K1 positive control homozygote 355TT, K2 positive
control heterozygote 355GT, K3 positive homozygote 355GG, 1+
homozygote 355TT, lanes 2,3,7 & 8 hetereozygote 355 GT, lanes 4-
6&9homozygote 355 GG, K0 negative control, MD pUC Mix 8
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duct was too small to be readily detected using this
approach (see Fig 2). In addition, randomly selected
cases with G/G, C/C and C/G variants were sequenced
(as described above) in order to confirm the presence of
the R48G change (data not shown). The 432C > G
change was identified using a similar protocol but the
enzyme used for the RFLP was the OliI restriction endo-
nuclease (Fermentas, St Leon Rot, Germany) which
resulted in two fragments of 132 bp and 491 bp in size
in samples that contained the C nucleotide (see Fig 3).
Randomly selected cases with G/G, C/C and C/G var-
iants were sequenced in order to confirm the presence
of the 432G > C change.
Statistical analysis
The frequencies of the individual genotypes were com-
pared between the cases and controls. Statistical signifi-
cance of the odds ratios were tested using the chi-
squared analysis (with Yates correction for continuity)
and Fisher’s exact test, where appropriate. Bonferroni
correction was applied to take into account multiple
testing.
Eight haplotypes could be generated from the three
SNPs. The frequencies of each of these were estimated
in the cases and controls using the genetic statistical
package haplo.stats for R http:// cran.r-project.org/src/
contrib/Descriptions/haplo.stats.html as reported by
Schaid et al. [10]. The CGG haplotype was the most
common and was used as the standard by which the
odds ratios were calculated. The association between the
presence of a particular haplotype and cancer risk was
determined by the haplo.stats software using a score test
(haplo.score) included in the package which is designed
to detect statistically significant differences in the distri-
bution of the estimated haplotype frequencies. Each of
the three SNPs was in Hardy-Weinberg equilibrium in
the cases and controls.
Each SNP of the CYP1B1 gene generated three geno-
types, including two homozygote states and one
heterozygote state. For each SNP, for each site, the odds
ratio and 95% confidence intervals were constructed.
For these comparisons, the most common allele was
considered to be the normal allele and odds ratios were
constructed with reference to individuals with two com-
mon alleles. The control population for this study was
used to determine the relative frequency of the CYP1B1
alleles in the underlying Polish population.
Results
For each individual SNP genotyped no significant asso-
ciation between it and colorectal cancer was observed
(see Table 2) suggesting that disease risk was not influ-
e n c e db ya n yo ft h eS N P sa l o n e .T h i ss u g g e s t st h a tt h e
resultant affect of each of the polymorphisms alone on
protein function was, at best, weak. Since each SNP cho-
sen for this investigation has previously been associated
with a change of function in the CYP1B1 gene, a geno-
type analysis was undertaken comparing two SNPs that
were in proximity to one another to determine if the
c o m b i n a t i o no ft w oS N P sw a sm o r el i k e l yt ob ea s s o -
ciated with disease risk. This analysis entailed assessing
Figure 2 Representative gel of RFLP-PCR for 142C > G (R48G).
Lanes: K0 negative control, K+ positive control (heterozygote
142CG), MD pUC Mix 8, 1 homozygote 142CC, 2 homozygote
142CC, 3 homozygote 142CC, 4 homozygote 142GG, 5 homozygote
142GG, 6 heterozygote 142CG, 7 heterozygote 142CG.
Figure 3 Representative gel of RFLP-PCR for change CYP1B1-
V432L (4329G > C). Lanes MD pUC Mix 8, K+ positive control
heterozygote 4329 GC (V432L), K0 negative control. Labes 1,2, 4-6
heterozygote 4329GC, lanes 3,7 homozygote 4329GG, lane 8
homozygote 4329CC
Table 2 Odds ratios for colorectal cancer associated with
the three CYP1B1 genotypes
SNP CASES CONTROLS OR P-VALUE 95%CI
N = 597 N = 597
rs10012 CC 261 265 0.9 0.9 0.9-1.1
GC 266 265 1.0 1.0 0.8-1.2
GG 70 67 1.0 0.8 0.7-1.5
rs1056827 GG 249 277 0.8 0.1 0.6-1.0
TG 271 259 1.0 0.5 0.9-1.4
TT 77 61 1.3 0.2 0.9-1.8
rs1056836 CC 214 206 1.0 0.7 0.8-1.3
CG 275 265 1.0 0.6 0.8-1.3
GG 108 127 0.8 0.9 0.6-1.0
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to determine if these combinations were associated with
CRC risk. The most significant finding of this analysis
was the identification of three genotypes, two of which
were associated with an increased risk of disease and
one that was protective (see Table 3). The combination
of homozygous wild type rs10012 and heterozygous
rs1056827 was associated with a significant increase in
CRC risk OR 2.4 CI 1.41-4.05; P 0.001. When rs1056827
SNP was present in the homozygous state an even
greater effect was observed (OR 7.1 CI 1.61-31.58;
P = 0.04).
When rs1056827 was investigated with rs1056836 a
similar trend was forthcoming (Table 4), where homozy-
g o u sc a r r i e r so ft h er s 1 0 5 6 8 2 7S N Pw e r em o r el i k e l yt o
develop colorectal cancer compared to there wild type
counterparts OR 10.2 CI 1.295-79.61; P = 0.09, after
Bonferroni correction) in the presence of homozygote
carriers of the rs1056836 SNP. In support of this obser-
vation, a similar trend for heterozygote carriers of the
rs1056836 allele was also observed in the colorectal
cancer group (OR 6.1 CI 1.36-27.39; P = 0.12, after Bon-
ferroni correction). Interestingly, individuals who were
heterozygous for rs1056836 and 1056827 but wild type
for rs10012 were not associated with an increased risk
of disease.
In order to determine if there were groups of indivi-
duals who may be greater risk by being homozygous for
all three SNPs we investigated the combination of
homozygote carriers against each other, where the wild
type haplotypes were considered to represent population
risk (see Table 5). This analysis was restricted as a result
of there being too few homozygote carriers available to
undertake an exhaustive analysis of disease risk con-
ferred by all possible combinations of genotypes. Not-
withstanding, we were able to examine enough patients
and controls to determine that homozygous for the fol-
lowing haplotype C-T-G appeared to be significantly at
risk of developing colorectal cancer (OR 21.4 CI 1.2-
365.56; P = 0.0019). The combination of being homozy-
gote for rs1056827 and rs1056836 SNPs did not appear
to be at any increase risk of disease.
Table 3 Analysis of genotypes R48G and A119 S and frequency in colorectal cancer
CYP1B1 CASES n = 597 CONTROL n = 597 STATYSTICAL ANALYSIS
rs10012 rs1056827 n Frequency
[%]
n Frequency
[%]
OR p-value
GG 199 33.3 241 40.4 0.7 0.08*
CC GT 48 8.0 21 3.5 2.4 0.001*
TT 14 2.4 2 0.3 7.1 0.004*
GG 38 6.4 29 4.9 1.3 0.3
CG GT 216 36.2 233 39.0 0.9 0.3
TT 12 2.0 4 0.7 3.0 0.1
GG 12 2.0 6 1.0 2.0 0.2
GG GT 7 1.2 6 1.0 1.2 1.0
TT 51 8.54 55 9.2 0.9 0.7
* after Bonferroni correction
Table 4 Analysis of genotypes A119 S and V432L and frequency in colorectal cancer
CYP1B1 CASES n = 597 CONTROL n = 597 STATYSTICAL ANALYSIS
rs1056827 rs1056836 n Frequency
[%]
n Frequency
[%]
OR p-value
CC 60 10.05 45 7.5 1.4 0.2
GG GC 103 17.2 119 20.0 0.8 0.3
GG 86 14.4 112 18.8 0.7 0.1
CC 99 16.6 103 17.3 1.0 0.8
GT GC 160 26.8 143 24.0 1.2 0.3
GG 12 2.0 14 2.4 0.9 0.8
CC 55 9.2 58 9.7 0.9 0.8
TT GC 12 2.0 2 0.3 6.1 0.12#
GG 10 0.8 1 0.2 10.2 0.09^
# before Bonferroni correction 0.015
^ before Bonferroni correction 0.011
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This study examines the potential influence of CYP1B1
genetic variants alone, and in combination, on colorectal
cancer risk. Each of the three SNPs when considered
individually appeared not to be associated with disease
risk for colorectal cancer. When considered together,
the magnitude of the colorectal cancer risk appeared to
be consistent yet modest. One previous report of
CYP1B1 and CRC risk provided some evidence for an
association with disease but this disappeared once a cor-
rection was applied for multiple testing [11]. The report
also concluded even though no unequivocal findings
were identified the role of CYP1B1 in colorectal cancer
risk could not be ruled out, especially in light of histo-
pathological evidence indicating that CYP1B1 is over-
expressed in colorectal cancers [12].
Several studies have examined the relationship
between individual CYP1B1 polymorphisms and cancer
risk [12-17]. The strength of the current study is the
investigation of three CYP1B1 SNPs in an ethnically-
homogeneous population of controls and patients with
one of the most frequently observed malignancies in
Poland. The effects of the three SNPs appear modest
and would not have been identified in smaller studies.
The variants in codons 119 and 432 are associated
with different substrate specificities and consequently
the catalytic activity of the enzyme [16,17]. There is evi-
dence that the CYP1B1 variants R48G, A119 S and
L432V all exhibit greater catalytic 4-hydoxylation activ-
ity than the wild type enzyme [8], which may provide a
functional clue as to why there appears to be an, albeit
small, association with disease risk.
Finally, in studies similar to the one reported herein it
would have been improved by including the effects of
environmental factors on disease risk. The current study
was not intended to address environmental influences
on disease risk rather to determine whether or not there
is an over-representation of genetic markers in a case
compared to a control population thereby providing
information on the relative involvement of the genetic
marker on disease risk.
In summary, the CYP1B1 variants examined in this
study suggest that they contribute to inter-individual
differences in cancer risk and are potentially valuable in
genetic risk assessment. These findings have potentially
important implications for genetic risk assessment and
for prevention studies, but it is important that they be
confirmed in other colorectal cancer populations prior
to introducing them in the clinical setting.
Conclusion
Genetic variants within the CYP1B1 that are associated
with altered function appear to influence susceptibility
to a colorectal cancer in Poland. Three haplotypes were
associated with altered cancer risk; one conferred pro-
tection and two were associated with an increased risk
of disease. These observations should be confirmed in
other populations.
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